Known targets — ChEMBL curated mechanism
EGFREPHA1EPHA10EPHA2EPHA3EPHA4EPHA5EPHA6EPHA7EPHA8EPHB1EPHB2EPHB3EPHB4EPHB6ERBB2ERBB3ERBB4FLT1FLT4KDRPTK6RETSRCTEK
The experimentally established mechanism targets of Vandetanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 16/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 13/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 11/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 11/20 | 1.00 |
| ▸ | RET known ✓ | P07949 | 3/20 | 1.00 |
| ▸ | EPHA2 known ✓ | P29317 | 3/20 | 1.00 |
| ▸ | EPHB4 known ✓ | P54760 | 3/20 | 1.00 |
| ▸ | TEK known ✓ | Q02763 | 2/20 | 1.00 |
| ▸ | EPHB6 known ✓ | O15197 | 1/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 1.00 |
| ▸ | SRC known ✓ | P12931 | 1/20 | 1.00 |
| ▸ | EPHA1 known ✓ | P21709 | 1/20 | 1.00 |
| ▸ | ERBB3 known ✓ | P21860 | 1/20 | 1.00 |
| ▸ | EPHA3 known ✓ | P29320 | 1/20 | 1.00 |
| ▸ | EPHA8 known ✓ | P29322 | 1/20 | 1.00 |
| ▸ | EPHB2 known ✓ | P29323 | 1/20 | 1.00 |
| ▸ | EPHA5 known ✓ | P54756 | 1/20 | 1.00 |
| ▸ | EPHB1 known ✓ | P54762 | 1/20 | 1.00 |
| ▸ | EPHA4 known ✓ | P54764 | 1/20 | 1.00 |
| ▸ | PTK6 known ✓ | Q13882 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vandetanib SCHEMBL9044 | 1.00 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL28224661 | 1.00 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL1614458 | 0.99 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL4637084 | 0.99 | EGFR (0.98) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL1783178 | 0.94 | EGFR (0.89) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL4544070 | 0.93 | EGFR (0.87) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL1614619 | 0.93 | EGFR (0.86) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL26359052 | 0.92 | EGFR (0.85) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL12534441 | 0.92 | EGFR (0.85) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL27218180 | 0.91 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 764 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326778-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2025-10-23 | — | — | US | claimed |
| US-20250308632-A1 | PROGNOSIS AND TREATMENT OF MOLECULAR SUBTYPES OF PROSTATE CANCER | VERACYTE INC (US) | 2025-10-02 | — | — | US | claimed |
| US-20250275955-A1 | USE OF TIVOZANIB TO TREAT SUBJECTS WITH REFRACTORY CANCER | AVEO PHARMACEUTICALS INC (US) | 2025-09-04 | — | — | US | claimed |
| EP-4552631-A2 | COMBINATION OF DASATINIB AND ADAGRASIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER | Mirati Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | claimed |
| EP-4522773-A1 | PROGNOSIS AND TREATMENT OF MOLECULAR SUBTYPES OF PROSTATE CANCER | Veracyte, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| US-20250034100-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2025-01-30 | — | — | US | claimed |
| US-20240293419-A1 | COMBINATION THERAPY FOR TREATING CANCER | EPIZYME INC (US) | 2024-09-05 | — | — | US | claimed |
| CN-118434765-A | BCMA monoclonal antibodies and antibody-drug conjugates | 杭州多禧生物科技有限公司 | 2024-08-02 | — | — | CN | claimed |
| EP-4378957-A2 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 | Novartis AG (CH) | 2024-06-05 | — | — | EP | claimed |
| CN-110612124-B | Optimized antibody compositions for treating ocular disorders | 豪夫迈·罗氏有限公司 | 2024-04-16 | — | — | CN | claimed |
| US-11377428-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | claimed |
| US-11370764-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS INC. (US) | 2022-06-28 | — | — | US | claimed |
| US-11370765-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | claimed |
| EP-4013879-A1 | METHODS AND COMPOSITIONS FOR REDUCING GENE OR NUCLEIC ACID THERAPY-RELATED IMMUNE RESPONSES | Generation Bio Co. (US) | 2022-06-22 | — | — | EP | claimed |
| US-20220185804-A1 | BENZAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-06-16 | — | — | US | claimed |
| CN-216724647-U | Be applied to cilium medicine-carrying spring coil of moving vein malformation intervention treatment | 上海交通大学医学院附属第九人民医院 | 2022-06-14 | — | — | CN | claimed |
| US-11332451-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (GA) | 2022-05-17 | — | — | US | claimed |
| WO-2022087371-A1 | NOVEL BICYCLIC COMPOUNDS | SPECTRUM PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| WO-2022087375-A1 | NOVEL HETEROCYCLIC COMPOUNDS | SPECTRUM PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| US-11299486-B2 | Benzazole compounds and methods for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-04-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299486-B2 | Benzazole compounds and methods for making and using the compounds | IRAK3, IRAK1, IRAK2 | EGFR 3266/4885KDR 3200/4885FLT1 3084/4885 |
| US-20250275955-A1 | USE OF TIVOZANIB TO TREAT SUBJECTS WITH REFRACTORY CANCER | PBK, PDCD1LG2, CD274 | EGFR 39/4885KDR 119/4885FLT1 678/4885 |
| US-20250326778-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | EGFR 2761/4885KDR 3383/4885FLT1 2893/4885 |
| US-20240293419-A1 | COMBINATION THERAPY FOR TREATING CANCER | EZH2, BMI1, DOT1L | EGFR 166/4885KDR 17/4885FLT1 43/4885 |
| US-20220185804-A1 | BENZAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | EGFR 3266/4885KDR 3200/4885FLT1 3084/4885 |
| US-11377428-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | EGFR 2739/4885KDR 2403/4885FLT1 1598/4885 |
| US-11332451-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | EGFR 2739/4885KDR 2403/4885FLT1 1598/4885 |
| US-20250034100-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | EGFR 2739/4885KDR 2403/4885FLT1 1598/4885 |
| US-11370764-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | EGFR 2739/4885KDR 2403/4885FLT1 1598/4885 |
| US-11370765-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | EGFR 2739/4885KDR 2403/4885FLT1 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.